passages: 65
passages: document
passages: The role of somatostatin ( octreotide ) in the regulation of melatonin secretion in healthy volunteers and in patients with primary hypothyroidism . Somatostatin has been found in the pineal gland of several animal species , which suggests that it may be involved in the regulation of melatonin secretion . Whether somatostatin has regulatory influence on melatonin secretion in man has never been unequivocally shown . We studied the nocturnal melatonin secretion in 8 healthy volunteers , and 6 women with untreated primary hypothyroidism , a disease state that is associated with increased nocturnal secretion of melatonin . The participants were given subcutaneous injections at 18:00 h and 23:00 h of either saline or octreotide ( Sandostatin ; each injection 50 microg ) . During the nights when the healthy volunteers were given octreotide , melatonin secretion was similar to that recorded during administration of saline . Also the urinary excretion of melatonin was of similar magnitude at these two occasions . By contrast , the GH secretion was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) . The patients with hypothyroidism also showed similar nocturnal melatonin secretion during octreotide and saline . Urinary excretion of melatonin also remained unchanged , as did GH secretion . The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin . Since exogenous somatostatin -- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .
entities: 66
entities: Intervention_Pharmacological
entities: somatostatin ( octreotide )
entities: 67
entities: Intervention_Pharmacological
entities: Somatostatin
entities: 68
entities: Intervention_Pharmacological
entities: somatostatin
entities: 69
entities: Intervention_Control
entities: saline
entities: 70
entities: Intervention_Pharmacological
entities: octreotide ( Sandostatin ;
entities: 71
entities: Intervention_Pharmacological
entities: octreotide
entities: 72
entities: Intervention_Control
entities: saline .
entities: 73
entities: Intervention_Pharmacological
entities: octreotide
entities: 74
entities: Intervention_Pharmacological
entities: octreotide
entities: 75
entities: Intervention_Control
entities: saline ;
entities: 76
entities: Intervention_Pharmacological
entities: octreotide
entities: 77
entities: Intervention_Control
entities: saline .
entities: 78
entities: Intervention_Pharmacological
entities: octreotide
entities: 79
entities: Intervention_Pharmacological
entities: octreotide
entities: 80
entities: Intervention_Control
entities: saline ;
entities: 81
entities: Intervention_Pharmacological
entities: octreotide
entities: 82
entities: Intervention_Pharmacological
entities: somatostatin .
entities: 83
entities: Intervention_Pharmacological
entities: somatostatin
entities: 84
entities: Intervention_Pharmacological
entities: octreotide
entities: 85
entities: Intervention_Pharmacological
entities: somatostatin
entities: 86
entities: Outcome_Physical
entities: melatonin secretion
entities: 87
entities: Outcome_Physical
entities: melatonin secretion .
entities: 88
entities: Outcome_Physical
entities: melatonin secretion
entities: 89
entities: Outcome_Physical
entities: nocturnal melatonin secretion
entities: 90
entities: Outcome_Physical
entities: melatonin secretion
entities: 91
entities: Outcome_Physical
entities: urinary excretion of melatonin
entities: 92
entities: Outcome_Physical
entities: GH secretion
entities: 93
entities: Outcome_Physical
entities: nocturnal melatonin secretion
entities: 94
entities: Outcome_Physical
entities: Urinary excretion of melatonin
entities: 95
entities: Outcome_Physical
entities: total nocturnal secretion of TSH
entities: 96
entities: Outcome_Physical
entities: nocturnal secretion and urinary excretion of melatonin
entities: 97
entities: Participant_Condition
entities: healthy volunteers and in patients with primary hypothyroidism .
entities: 98
entities: Participant_Sample-size
entities: 8
entities: 99
entities: Participant_Condition
entities: healthy volunteers
entities: 100
entities: Participant_Sample-size
entities: 6
entities: 101
entities: Participant_Sex
entities: women
entities: 102
entities: Participant_Condition
entities: untreated primary hypothyroidism
entities: 103
entities: Participant_Condition
entities: healthy volunteers
entities: 104
entities: Participant_Condition
entities: patients with hypothyroidism
entities: 105
entities: Participant_Condition
entities: normal subjects and in patients with primary hypothyroidism